Photo: Business Insider India
Covaxin 81% Effective Against COVID-19 UK Strain In Phase-3 Trials
Indian pharmaceutical giant Bharat Biotech has claimed 81% efficacy against COVID-19 for its vaccine 'Covaxin'. Releasing the phase three clinical data of the vaccine on March 3, the company claimed the vaccine of being effective against the UK variants of the virus. While peer reviews are still awaited, the developer conducted clinical trials on over 25,800 people. Reportedly, Indian drug regulator DCGI earlier approved the Covaxin for… read-more
Tags: Bharat biotech, Covaxin, Health, Covid-19, Coronavirus Vaccines
Courtesy: NDTV
Photo: Radio Free Europe
India Invites Pakistani Diplomats For COVID Vaccination Offer
As a part of diplomatic goodwill gesture, India has sent invitations to Delhi-based Pakistani delegates for the COVID-19 vaccination offer. However, Pakistan is yet to respond to the offer. Reportedly, Pakistan commenced its inoculation drive with 50,000 doses of Chinese 'Sinopharm' vaccine on February 2. Earlier in December 2020, India toured over 50 foreign diplomats to two vaccine producing sites in Hyderabad - Bharat Biotech and… read-more
Tags: Covid-19 Vaccination, Sinopharm Vaccine, Bharat biotech, Biological E, Hyderabad
Courtesy: WION
Photo: Yahoo News
Britain's GSK Shifts Production Of Malaria Vaccine To Bharat Biotech
Britain’s pharmaceutical company GlaxoSmithKline on January 27 agreed to transfer the production of world’s first effective malaria vaccine to India’s Bharat Biotech. While GSK will shift the manufacturing of the protein part of the vaccine, it will supply the immunological agent/vaccine booster to the India-based manufacturer. Reportedly, Bharat Biotech may become the sole supplier of the malaria vaccine by 2029, while GSK will continue to… read-more
Tags: Bharat biotech, Malaria, Britain, GSK
Courtesy: WION
Photo: The Tribune India
Bharat Biotech Seek Permit For Nasal COVID Vaccine's Phase 1 Trial
COVID-19 vaccine developer Bharat Biotech has applied to the Drug Controller General of India for Phase 1 trial of its intranasal COVID-19 vaccine. Touted as a potential game-changer, the vaccine is a pain-free needle-less method and does not require trained healthcare workers. Citing the efficacy on tests results done on rodents, Bharat Biotech said it could stimulate an immune response in the nose by protecting the point of entry of the… read-more
Tags: Bharat biotech, Nasal Vaccine, Phase 1 Trial, Covid-19
Courtesy: DT NEXT
Photo: India TV
Bharat Biotech Assure Compensation For Covaxin's Side Effects
Covaxin manufacturer Bharat Biotech has promised to compensate vaccine recipients if they experience any adverse effects post-vaccination as mentioned in its consent form. However, the company has advised the recipients to follow Covid-19 norms even after inoculation the vaccine. Reportedly, Centre has ordered a supply of 55 lakh doses of Covaxin considering the vaccine's efficacy which is still under the phase-three of clinical trials.
Tags: Bharat biotech, Covaxin, Covid-19 Vaccine, Health
Courtesy: The Indian Express
Photo: The Indian Express
COVID-19: Bharat Biotech Provides 16.5 Lakh Covaxin Doses To India
Vaccine developer Bharat Biotech on January 13 provided 16.5 lakh doses of its COVID-19 vaccine 'Covaxin’ to the Government of India. Moreover, the company acknowledged the nation, partners, and volunteers of clinical trials for making the first indigenous vaccine a success. The vaccine developer also announced successful air-shipment of the vaccine to 11 Indian cities including Bengaluru, Jaipur, Chennai, and Pune. Reportedly, the Centre had… read-more
Tags: Covaxin, Bharat biotech, Covid Vaccine, Vaccination
Courtesy: India Today
Photo: Asianet Newsable
People May Not Have Option To Choose From COVID Vaccines, Hints Govt
Stating that no other country with two or more vaccines has given an option, the health ministry representative on January 12 hinted that India will not provide option to choose between COVID-19 vaccines. Addressing a press conference, Health Secretary Rajesh Bhushan said both the vaccines of India are equally safe and there is no risk. Reportedly, the government will procure 110 lakh doses from Serum Institute of India and 55 lakh doses from… read-more
Tags: Covid-19 Vaccine, Covaxin, Bharat biotech, Serum Institute of India
Courtesy: The Times of India
Photo: India Today
Bharat Biotech CMD Slams People Doubting Over 'Covaxin' Efficacy
Slamming reports criticizing Bharat Biotech's Covaxin, Chairman of the company Dr Krishna Ella stated the vaccine is nowhere inferior to Pfizer’s COVID-19 vaccine. In the press conference addressed by Dr Ella on January 4, he expressed his anger over people for "gossiping" and backlashing Indian companies. Speaking on transparency, he said that more than 70 articles had been published and Bharat Biotech conducted trials in over 12 countries… read-more
Tags: Bharat biotech, Covaxin, Coronavirus, Pfizer, Covid-19
Courtesy: Livemint
Photo: Nairametrics
Brazilian Clinics' Association Approaches Bharat Biotech For Covaxin
Soon after Bharat Biotech-developed COVID vaccine, 'Covaxin', received Indian drug regulator's nod, Brazilian Association of Vaccine Clinics (ABCVAC) signed an agreement with the company to purchase the vaccine. The ABCVAC, on its website, confirmed about the agreement. "We had been looking for solutions ...and the possibility came up of using this Indian Vaccine, which is very promising," said the association president. However, Brazil's… read-more
Tags: Bharat biotech, ABCVAC, Covaxin, Brazil
Courtesy: WION
Photo: Telegraph India
MP Tharoor Warns Health Ministry Over Approval Of Premature Covaxin
Reacting to emergency approval of COVID-19 vaccines, Congress MP Shashi Tharoor said the premature authorization of ‘Covaxin’ may be unsafe as it is still undergoing the Phase-3 clinical trials. Moreover, he requested Health Minister Harsh Vardhan to wait for the final stage of Covaxin, meanwhile resort to the AstraZeneca vaccine. Earlier, Indian Drug Controller General had announced emergency and restricted use of COVID vaccines from Serum… read-more
Tags: Serum Institute of India, Bharat biotech, Covaxin, Dr Shashi Tharoor, Dr Harsh Vardhan
Courtesy: Hindustan Times